JP2017505620A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505620A5
JP2017505620A5 JP2016549077A JP2016549077A JP2017505620A5 JP 2017505620 A5 JP2017505620 A5 JP 2017505620A5 JP 2016549077 A JP2016549077 A JP 2016549077A JP 2016549077 A JP2016549077 A JP 2016549077A JP 2017505620 A5 JP2017505620 A5 JP 2017505620A5
Authority
JP
Japan
Prior art keywords
recombinant protein
culture
transfected
days
mammalian host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549077A
Other languages
English (en)
Japanese (ja)
Other versions
JP6474420B2 (ja
JP2017505620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/069744 external-priority patent/WO2015116315A1/en
Publication of JP2017505620A publication Critical patent/JP2017505620A/ja
Publication of JP2017505620A5 publication Critical patent/JP2017505620A5/ja
Application granted granted Critical
Publication of JP6474420B2 publication Critical patent/JP6474420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549077A 2014-01-29 2014-12-11 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現 Active JP6474420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
US61/933,137 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019011871A Division JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現

Publications (3)

Publication Number Publication Date
JP2017505620A JP2017505620A (ja) 2017-02-23
JP2017505620A5 true JP2017505620A5 (enExample) 2017-11-30
JP6474420B2 JP6474420B2 (ja) 2019-02-27

Family

ID=53757626

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549077A Active JP6474420B2 (ja) 2014-01-29 2014-12-11 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現
JP2019011871A Active JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現
JP2020190707A Active JP7034236B2 (ja) 2014-01-29 2020-11-17 組換えタンパク質のグリコシル化を調節するためのn-グリコシル化経路制御因子の過剰発現
JP2022029077A Active JP7788307B2 (ja) 2014-01-29 2022-02-28 組換えタンパク質のグリコシル化を調節するためのn-グリコシル化経路制御因子の過剰発現

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019011871A Active JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現
JP2020190707A Active JP7034236B2 (ja) 2014-01-29 2020-11-17 組換えタンパク質のグリコシル化を調節するためのn-グリコシル化経路制御因子の過剰発現
JP2022029077A Active JP7788307B2 (ja) 2014-01-29 2022-02-28 組換えタンパク質のグリコシル化を調節するためのn-グリコシル化経路制御因子の過剰発現

Country Status (14)

Country Link
US (3) US10227627B2 (enExample)
EP (1) EP3099806A1 (enExample)
JP (4) JP6474420B2 (enExample)
KR (3) KR102301034B1 (enExample)
CN (2) CN106170554B (enExample)
AU (3) AU2014380174C1 (enExample)
BR (1) BR112016017606A2 (enExample)
CA (1) CA2938079C (enExample)
CL (1) CL2016001900A1 (enExample)
EA (2) EA037565B1 (enExample)
IL (3) IL282517B (enExample)
MX (2) MX377780B (enExample)
SG (1) SG10201912081RA (enExample)
WO (1) WO2015116315A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251537A1 (en) * 2019-06-10 2020-12-17 CHO Plus Inc. Cell lines for high level production of protein-based pharmaceuticals
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
AU2018235928B2 (en) * 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗tslp抗體組成物及其用途
WO2026130515A1 (en) * 2024-12-20 2026-06-25 Wuxi Biologics (Shanghai) Co., Ltd. Nucleic acid construct, vector, and approach to reduce high mannose of recombinant protein

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
PL1720972T3 (pl) * 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
US9034341B2 (en) * 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
AU2011237442A1 (en) * 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
TW201209160A (en) 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
SG11201403814RA (en) 2012-01-11 2014-10-30 Sigma Aldrich Co Llc Production of recombinant proteins with simple glycoforms

Similar Documents

Publication Publication Date Title
TWI702226B (zh) 治療性蛋白質藥物物質之整合連續製造
Clincke et al. Very high density of Chinese hamster ovary cells in perfusion by alternating tangential flow or tangential flow filtration in WAVE bioreactor™—part II: applications for antibody production and cryopreservation
JP2016104045A5 (enExample)
JP6472786B2 (ja) 抗体の精製及び純度のモニタリング
TWI720289B (zh) 用於增加重組蛋白質之甘露糖含量之方法
Fliedl et al. Human cell lines for the production of recombinant proteins: on the horizon
JP2021517805A5 (enExample)
JP2017538446A5 (enExample)
WO2008091740A4 (en) Polyelectrolyte precipitation and purification of antibodies
WO2015004679A1 (en) Improved process for production of monoclonal antibodies
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
PH12015501837B1 (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
Zydney Membrane technology for purification of therapeutic proteins
JP2016512848A5 (enExample)
IL310186B1 (en) Plasma kallikrein binding proteins
WO2013093760A3 (en) Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6474420B2 (ja) 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現
BR112012011980A2 (pt) Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas
JP2015532096A5 (enExample)
IL276211B1 (en) Process for producing hu14.18k322a monoclonal antibody
CN107384932B (zh) 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
Bosco et al. Alternating flow filtration as an alternative to internal spin filter based perfusion process: Impact on productivity and product quality
IL307155B2 (en) Antibodies with modulated glycan profiles
HRP20250491T1 (hr) Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina
US10421986B2 (en) Method for the clarification of high-density crude cell culture harvest